Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;104(5):e208-e210.
doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Maria Winqvist  1   2 , Per-Ola Andersson  3 , Anna Asklid  2 , Karin Karlsson  4 , Claes Karlsson  5   2 , Birgitta Lauri  6 , Jeanette Lundin  5   2 , Mattias Mattsson  7 , Stefan Norin  8 , Anna Sandstedt  9 , Richard Rosenquist  10 , Florentin Späth  11 , Lotta Hansson  5   2 , Anders Österborg  5   2 ; Swedish CLL Group
Affiliations

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Maria Winqvist et al. Haematologica. 2019 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival (PFS) and overall survival (OS) for patients included in the compassionate use program (CUP). Survival analyses from start of treatment until event using the Kaplan-Meier method. (A) PFS and (B) OS of all patients. (C) PFS and (D) OS of CUP patients matching versus not matching the RESONATE trial inclusion criteria. (E) PFS and (F) OS of CUP patients with dose reduction versus no dose reduction. (G) PFS and (H) OS of CUP patients with treatment break versus no treatment break.
See this image and copyright information in PMC

References

    1. Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–1580. - PMC - PubMed
    1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. - PMC - PubMed
    1. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. - PMC - PubMed
    1. Goede V, Bahlo J, Chataline V, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789–796. - PubMed
    1. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. - PMC - PubMed

Publication types

MeSH terms